Sneaky Entry of IFN Through Arsenic-Induced Leaky Blood-Brain Barrier Reduces CD200 Expression by Microglial pro-Inflammatory Cytokine

Recent studies showed that neuronal surface protein CD200 plays a key role in the regulation of neuroinflammation. Previously, we showed that arsenic (0.38mg/kg body weight) exposure induces microglial activation and consequently IL-6/TNF- secretion. This result indicated the possibility of alteration in the expression of CD200. Therefore, the present study was focused on checking arsenic-induced alteration in CD200 expression and revealing the underlying mechanism. Male BALB/c mice were exposed to arsenic (vehicle, 0.038 and 0.38mg/kg body weight) for 60days, and the expression level of CD200 was found to be decreased which was rescued by minocycline (33mg/kg body weight) co-administration. Higher CD68 staining, increased level of IL-6/TNF-, as well as higher level of IFN, were observed in in vivo arsenic-exposed groups. Interestingly, in vitro arsenic exposure could not increase IL-6/TNF- level in the culture supernatant, whereas, supplementation of IFN could mimic the in vivo results. However, arsenic could not induce IFN production from brain endothelial cells, microglia, and astrocytes, thereby suggesting the entry of IFN through the impaired blood-brain barrier. Evans blue fluorescence in the brain confirms altered blood-brain barrier permeability although no changes were observed in the expression level of tight junction proteins (claudin-5 and occludin). Finally, intracerebral injection of anti-IFN neutralizing antibody in arsenic-exposed brain reduced microglia activation (IL-6 and TNF- and CD68 expression) and subsequently rescued CD200 level. Taken together, the study showed that arsenic-mediated compromised blood-brain barrier is a major driving force to induce microglial IL-6 and TNF- production through serum IFN leading to CD200 downregulation.